Gijs Hubben

Modelling the Costs and Effects of Selective and Universal Hospital Admission Screening for Methicillin-Resistant Staphylococcus aureus

Background Screening at hospital admission for carriage of methicillin-resistant Staphylococcus aureus (MRSA) has been proposed as a strategy to reduce nosocomial infections. The objective of this study was to determine the long-term costs and health benefits of selective and universal screening for MRSA at hospital admission, using both PCR-based and chromogenic media-based tests in various settings. Methodology/Principal Findings A simulation model of MRSA transmission was used to determine costs and effects over 15 years from a US healthcare perspective. We compared admission screening together with isolation of identified carriers against a baseline policy without screening or isolation. Strategies included selective screening of high risk patients or universal admission screening, with PCR-based or chromogenic media-based tests, in medium (5%) or high nosocomial prevalence (15%) settings. The costs of screening and isolation per averted MRSA infection were lowest using selective chromogenic-based screening in high and medium prevalence settings, at

Diagnostic accuracy of culture-based and PCR-based detection tests for methicillin-resistant Staphylococcus aureus: a meta-analysis.

4,100 and

Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands.

10,300, respectively. Replacing the chromogenic-based test with a PCR-based test costs

The societal burden of HIV/AIDS in Northern Italy: An analysis of costs and quality of life

13,000 and

AIDSIMPACT SPECIAL ISSUE The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life

36,200 per additional infection averted, and subsequent extension to universal screening with PCR would cost

Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands

131,000 and

Development of a web‐based application and multicountry analysis framework for assessing interdicted infections and cost‐utility of screening donated blood for HIV , HCV and HBV

232,700 per additional infection averted, in high and medium prevalence settings respectively. Assuming

BLOOD DONORS AND BLOOD COLLECTION: Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands: WEB INTERFACE-SUPPORTED DECISION MAKING

17,645 benefit per infection averted, the most cost-saving strategies in high and medium prevalence settings were selective screening with PCR and selective screening with chromogenic, respectively. Conclusions/Significance Admission screening costs

Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening

4,100–

BLOOD DONORS AND BLOOD COLLECTION: Web interface–supported transmission risk assessment and cost‐effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands

21,200 per infection averted, depending on strategy and setting. Including financial benefits from averted infections, screening could well be cost saving.